Meet the 2022 Laureates: Lourdes Ibáñez, MD, PhD

Ibanez_Laureate2022

Lourdes Ibáñez, MD, PhD 

International Excellence in Endocrinology Award

Lourdes Ibáñez, MD, PhD, is a pediatric endocrinologist at Sant Joan de Déu Barcelona Hospital and chairman of Pediatrics, chair of Clinical Research in Endocrinology at the University of Barcelona in Barcelona, Spain.

A worldwide leader in the field of polycystic ovary syndrome, Ibáñez pioneered the use of combined, low-dose insulin sensitization for the treatment of the disease — a novel therapeutic approach directed to the pathophysiology of the disorder. 

In 2002, Ibáñez started the Fellowship Program in Pediatric Endocrinology & Diabetes of the University of Barcelona and has since mentored 22 fellows from Latin America.  

How has the Endocrine Society supported your professional development/career journey?

I have been attending the Endocrine Society meeting from more than 25 years. In every meeting, there was a topic(s) in the program that became a source of inspiration for further research back at home. In addition, ENDO has prompted the development of collaborations with other researchers and thus contributed to expand the horizon of my research program, too.

As a Laureate Award recipient, do you have any advice for those just beginning their careers?

Have an objective; be persistent and work a lot. Failures do indeed generate new strength.

You may also like

  • Holly A. Ingraham, PhD, Receives FASEB Excellence in Science Lifetime Achievement Award

    Endocrine Society member Holly A. Ingraham, PhD, is the recipient of the FASEB Excellence in Science Lifetime Achievement Award. On April 8, the organization announced the winners of its 2024 Excellence in Science Awards, which highlight outstanding achievements by women in biological sciences who demonstrate not only excellence and innovation in their research fields, but…

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

Find more in